An open trial of paroxetine in the treatment of children and adolescents diagnosed with dysthymia.
This open-label study examined the potential efficacy of paroxetine in the treatment of children and adolescents diagnosed with dysthymia over a period of 3 months. Seven subjects were evaluated by the Hamilton Depression Rating Scale (HAM-D), by the Clinical Global Impression Severity of Illness Scale (CGI-S), and the Clinical Global Impression Improvement Scale (CGI-I). Seventy-one percent of patients had a satisfactory response, suggesting the efficacy of paroxetine in children with dysthymia.
Nobile
M
M
Child Psychiatry Unit, Istituto Scientifico Eugenio Medea, Bosisio Parini, Italy. mnobile@bp.lnf.it
Bellotti
B
B
Marino
C
C
Molteni
M
M
Battaglia
M
M
D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D019263:Dysthymic Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine